In September 2021, over 1,400 donors gave $535,588 in donations and pledges. We are so grateful to these supporters who advance our shared vision of creating safe and legal opportunities for the beneficial …
As leaders in psychedelic medicine, we embrace our obligation to provide patients a safe, supportive therapeutic context free from abuse and to cultivate ethical practices in psychedelic therapy. We are …
Psychedelic researcher Matthew W. Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine, recently received a grant from the National Institute on Drug Abuse …
In August 2021, MAPS raised $1,705,031 in donations and pledges from over 1,400 supporters. Of this amount: $782,969 is for MDMA-related projects; $451,685 is for general support; $300,010 is for health …
Over 300 clinicians and counselors just completed the 4 month MDMA Therapy Training Program online course. Congratulations! This cohort represented the largest of its kind and is part of an effort to train …
California Senate Bill SB 519, authored by Senator Scott Wiener (D-San Francisco), was put on hold and will now become a two-year bill. The legislation that would decriminalize several psychedelic substances …
Thank you to everyone who attended our EntheoGeneration 2021 sessions! EntheoGeneration is a psychedelic-inspired speaker series born at Burning Man in 2019. This year’s video recordings are now …
On August 17 and 18, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the MAPS-sponsored Phase 2 study of MDMA-assisted therapy for U.S. …
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
MAPS and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) have entered into a Memorandum of Understanding with Wesana Health Inc, a publicly traded, data-driven life …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
